Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Sarah HarrisGiancarlo ComiBruce A C CreeDouglas L ArnoldLawrence SteinmanJames K SheffieldHarry SouthworthLudwig KapposJeffrey A Cohennull nullPublished in: European journal of neurology (2021)
pNfL was associated with clinical and radiologic measures of disease and treatment effects in RMS, supporting its use as a biomarker.